Kite, A Gilead Company

Birmingham, Alabama

OncologyantibodyPhase III

What changed

Phase III trial registered: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

5d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

604 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Jun 12, 2026
Large B-cell Lymphoma, Follicular Lymphoma · AVAILABLE · sponsor: Kite, A Gilead Company · Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
ClinicalTrials.gov · NCT05776160 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 22, 2026
Relapsed or Refractory Large B-cell Lymphoma · RECRUITING · sponsor: Kite, A Gilead Company · Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
ClinicalTrials.gov · NCT07479797 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 10, 2026
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis · RECRUITING · sponsor: Kite, A Gilead Company · A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
ClinicalTrials.gov · NCT07304154 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 2, 2025
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy · ENROLLING_BY_INVITATION · sponsor: Kite, A Gilead Company · A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
ClinicalTrials.gov · NCT07038447 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 20, 2024
Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Kite, A Gilead Company · A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
ClinicalTrials.gov · NCT06539338 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 23, 2024
Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Kite, A Gilead Company · A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
ClinicalTrials.gov · NCT06413498 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 18, 2024
Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Kite, A Gilead Company · Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
ClinicalTrials.gov · NCT06253663 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 9, 2023
Relapsed/Refractory Large B-cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Kite, A Gilead Company · Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
ClinicalTrials.gov · NCT06079164 (opens the source filing in a new tab)
Trial
PHASE3 registered
Feb 10, 2023
High-risk Large B-cell Lymphoma (LBCL) · ACTIVE_NOT_RECRUITING · sponsor: Kite, A Gilead Company · Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
ClinicalTrials.gov · NCT05605899 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 9, 2022
Relapsed or Refractory Large B-cell Lymphoma · COMPLETED · sponsor: Kite, A Gilead Company · Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
ClinicalTrials.gov · NCT05459571 (opens the source filing in a new tab)
Trial
Study registered
Dec 15, 2021
Solid and Hematological Malignancies · ENROLLING_BY_INVITATION · sponsor: Kite, A Gilead Company · Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
ClinicalTrials.gov · NCT05041309 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Oct 27, 2021
Relapsed and/or Refractory B-cell Lymphoma · RECRUITING · sponsor: Kite, A Gilead Company · Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
ClinicalTrials.gov · NCT04989803 (opens the source filing in a new tab)
Trial
PHASE2 registered
Apr 27, 2021
Relapsed/Refractory Mantle Cell Lymphoma · COMPLETED · sponsor: Kite, A Gilead Company · Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
ClinicalTrials.gov · NCT04880434 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00name similarity 100% · semantic similarity 93% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 1.00name similarity 100% · semantic similarity 81% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the trial record at 0.98name similarity 100% · semantic similarity 84% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.92name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
new_entity links the trial record at 0.24same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
5d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
5d agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
3w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
4w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
5w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
5mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
8mo agoTrial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

Study registered

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE3 registered

PHASE2 registered

Study registered

PHASE1/PHASE2 registered

PHASE2 registered